RA Capital Management’s Sutro Biopharma STRO Stock Holding History

RA Capital Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-715,307	Closed	-$17.8M	–	93
2026 Q1	$17.8M	Buy	+715,307	New	+$12.9M	0.19%	61
2025 Q2	–	Sell	-443,464	Closed	-$2.89M	–	83
2025 Q1	$2.89M	Buy	+443,464	New	+$6.98M	0.05%	82
2021 Q2	–	Sell	-211,821	Closed	-$48.2M	–	99
2021 Q1	$48.2M	Hold	211,821	–	–	0.73%	40
2020 Q4	$46M	Hold	211,821	–	–	0.64%	41
2020 Q3	$21.3M	Buy	211,821 +19,857	+10%	+$1.88M	0.39%	47
2020 Q2	$14.9M	Buy	+191,964	New	+$18.4M	0.29%	46

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

RA Capital Management's STRO Position: Q2 2026 in Review

RA Capital Management sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 715,307 shares — an estimated $17.8M sold.

RA Capital Management first reported a position in STRO in Q2 2020 and held it in 6 quarters. The position peaked at $48.2M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

RA Capital Management reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
RA Capital Management sold 715,307 Sutro Biopharma shares in Q2 2026, an estimated $17.8M.
RA Capital Management first reported a position in Sutro Biopharma in Q2 2020 and held it in 6 quarters.
RA Capital Management's Sutro Biopharma position peaked at $48.2M in Q1 2021.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.